Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
3.98
+0.01 (0.25%)
Market open: Aug 12, 2026, 10:49 AM EDT
4.04
+0.07 (1.76%)
Previous after-hours: Aug 11, 2026, 7:40 PM EDT
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
| Name | Position |
|---|---|
| Dr. Jill E. Porter Ph.D. | Senior Vice President of CMC |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer |
| Dr. Michael Philip Dybbs Ph.D. | Co-Founder & Director |
| Dr. Napoleone Ferrara M.D. | Independent Director & Co-Founder |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director & Co-Founder |
| Mr. Andrew Oxtoby | President, CEO & Director |
| Ms. Amy Vandekop | Interim Principal Accounting Officer & Corporate Controller |
| Ms. Kristine Curtiss | Senior Vice President of Clinical |
| Ms. Liisa Ann Bayko M.B.A. | CFO & Treasurer |
| Date | Type | Document |
|---|---|---|
| 2026-08-11 | 8-K | d114296d8k.htm |
| 2026-07-20 | 8-K | d125092d8k.htm |
| 2026-07-17 | 8-K | d125006d8k.htm |
| 2026-07-06 | 8-K | d34897d8k.htm |
| 2026-06-04 | 8-K | d85626d8k.htm |
| 2026-05-12 | 8-K | d24879d8k.htm |
| 2026-05-12 | 10-Q | klrs-20260331.htm |
| 2026-04-24 | DEFA14A | d114103ddefa14a.htm |
| 2026-04-24 | DEF 14A | d113973ddef14a.htm |
| 2026-04-24 | ARS | d69530dars.pdf |